Renal denervation in internal medicine: a FADOI Position Paper on behalf of the Vicenza Hypertension Multidisciplinary Team. Endorsed by the Italian Society of Arterial Hypertension

Resistant hypertension (RH) remains a clinical challenge in internal medicine, associated with increased cardiovascular morbidity and mortality. Renal denervation (RDN), a catheter-based intervention targeting renal sympathetic nerves, has re-emerged as a promising “adjunctive” therapy following the publication of the latest sham-controlled randomized trials. Current data demonstrate that RDN provides a modest but consistent reduction in blood pressure, with a favorable safety profile in selected patients with RH and uncontrolled hypertension, despite optimized pharmacological therapy or in those with medication intolerance. This paper reviews the pathophysiological rationale, updated clinical evidence, patient selection criteria, procedural aspects, and future perspectives of RDN, for which a multidisciplinary approach is required to ensure procedural safety and optimal outcomes.

This position paper is not intended to be a new guideline but a practical recommendation on how to proceed with the selection of the patient candidate for RDN and his management before and after the procedure in internal medicine coordinated by a hypertension specialist.

Azizi M, Vongpatanasin W, Fisher NDL, et al. Diagnosis and management of resistant hypertension: a review. JAMA 2026;335:1428-39. DOI: https://doi.org/10.1001/jama.2026.1221

Grassi G. Role of the sympathetic nervous system in human hypertension. J Hypertens 1998;16:1979-87. DOI: https://doi.org/10.1097/00004872-199816121-00019

Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370:1393-401. DOI: https://doi.org/10.1056/NEJMoa1402670

Mancia G, Kreutz R, Brunström M, et al. 2023 ESH guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension. Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 2023;41:1874-2071. DOI: https://doi.org/10.1097/HJH.0000000000003480

McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024;45:3912-4018. DOI: https://doi.org/10.1093/eurheartj/ehae646

Jones DW, Ferdinand KC, Taler SJ, et al. 2025. AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the ACC/AHA Joint Committee on Clinical Practice Guidelines. Hypertension 2025;82:e212-316. DOI: https://doi.org/10.1161/HYP.0000000000000257

Weber MA, Mahfoud F, Schmieder RE, et al. Renal denervation for hypertension: current evidence. JACC Cardiovasc Interv 2019;12:1095-105. DOI: https://doi.org/10.1016/j.jcin.2019.02.050

Bhatt DL, Vaduganathan M, Kandzari DE, et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 trial. Lancet 2022;400:1405-16. DOI: https://doi.org/10.1016/S0140-6736(22)01787-1

Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 2017;390:2160-70. DOI: https://doi.org/10.1016/S0140-6736(17)32281-X

Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet 2020;395:1444-51. DOI: https://doi.org/10.1016/S0140-6736(20)30554-7

Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs (SPYRAL HTN-ON MED). Lancet 2018;391:2346-55. DOI: https://doi.org/10.1016/S0140-6736(18)30951-6

Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO). Lancet 2018;391:2335-45. DOI: https://doi.org/10.1016/S0140-6736(18)31082-1

Azizi M, Sanghvi K, Saxena M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO). Lancet 2021;397:2476-86. DOI: https://doi.org/10.1016/S0140-6736(21)00788-1

Azizi M, Saxena M, Wang Y, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE II): a randomised clinical trial. JAMA 2023;329:651-61. DOI: https://doi.org/10.1001/jama.2023.0713

Vukadinović D, Lauder L, Kandzari DE, et al. Effects of catheter-based renal denervation in hypertension: a systematic review and meta-analysis. Circulation 2024;150:1599-611. DOI: https://doi.org/10.1161/CIRCULATIONAHA.124.069709

Singh S, Rout A, Garg A. Renal denervation in hypertension: an updated meta-analysis of the randomized controlled trials. Catheter Cardiovasc Interv 2023;102:663-71. DOI: https://doi.org/10.1002/ccd.30796

Kiuchi MG. Renal denervation revisited. Kidney Res Clin Pract 2018;37:424-5. DOI: https://doi.org/10.23876/j.krcp.18.0103

Ahmad Y, Francis DP, Bhatt DL, et al. Renal denervation for hypertension: a systematic review and meta-analysis of randomised, blinded, placebo-controlled trials. JACC Cardiovasc Interv 2021;14:2614-24. DOI: https://doi.org/10.1016/j.jcin.2021.09.020

Sharp ASP, Fisher NDL. Renal denervation to treat hypertension: a clinical state-of-the-art review. Am J Hypertens 2026;39:355-64. DOI: https://doi.org/10.1093/ajh/hpaf134

Mazza A, Lenti S, D’Avino M, et al. Self-reported hypertension, dyslipidemia and hyperuricemia management by Italian Internal Medicine units: a national survey of the FADOI Study Group in Cardiovascular Medicine. Ital J Med 2017;11:371-9. DOI: https://doi.org/10.4081/itjm.2017.852

Pappaccogli M, Ponsa L, Goi J, et al. Management of renovascular hypertension and renal denervation in patients with hypertension: an Italian nationwide survey. High Blood Press Cardiovasc Prev 2024;31:501-12. DOI: https://doi.org/10.1007/s40292-024-00668-8

Negro A, Manari A, Santi R, et al. Endovascular radiofrequency renal denervation in resistant hypertension: a single center experience. Ital J Med 2014;8:29-34. DOI: https://doi.org/10.4081/itjm.2013.174

Bruno RM, Taddei S, Borghi C, et al. Italian Society of Arterial Hypertension (SIIA) position paper on the role of renal denervation in the management of the difficult-to-treat hypertensive patient. High Blood Press Cardiovasc Prev 2020;27:109-17. DOI: https://doi.org/10.1007/s40292-020-00367-0

Schmieder RE, Mahfoud F, Mancia G, et al. European Society of Hypertension position paper on renal denervation 2021. J Hypertens 2021;39:1733-41. DOI: https://doi.org/10.1097/HJH.0000000000002933

Stabile E, Muiesan ML, Ribichini FL, et al. Italian Society of Interventional Cardiology (GISE) and Italian Society of Arterial Hypertension (SIIA) consensus document on the role of renal denervation in the management of the difficult-to-treat hypertension. G Ital Cardiol 2023;24:53S-63S.

Ogoyama Y, Kario K. Aspects of renal function and renal artery anatomy as indications for renal denervation. Hypertens Res 2024;47:2711-7. DOI: https://doi.org/10.1038/s41440-024-01860-y

Petramala L, Olmati F, Galassi M, et al. The prevalence of resistant arterial hypertension and secondary causes in a cohort of hypertensive patients: a single center experience. Ital J Med 2017;11:380-7.

Rossi GP, Bisogni V, Bacca AV, et al. The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. Int J Cardiol Hypertens 2020;5:100029. DOI: https://doi.org/10.1097/01.hjh.0000745016.79540.85

De Nicola L, Gabbai FB, Agarwal R, et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol 2013;61:2461-7. DOI: https://doi.org/10.1016/j.jacc.2012.12.061

Schmieder RE. Renal denervation: where do we stand and what is the relevance to the nephrologist? Nephrol Dial Transplant 2022;37:638-44. DOI: https://doi.org/10.1093/ndt/gfaa237

Feriozzi S, Battaglia Y, Cirami CL, et al. The role of renal denervation for the treatment of hypertension in patients with chronic kidney disease: a position paper of the Italian Society of Nephrology. J Nephrol 2025;38:2053-65. DOI: https://doi.org/10.1007/s40620-025-02406-2

Mazza A, Giordan M, Dell’Avvocata F, et al. Renal denervation with CO2 technology in a patient with chronic renal failure, renal artery stenosis and allergy to iodinated contrast medium: from theory to practice. High Blood Press Cardiovasc Prev 2025;32:759.

Gonzálvez-García A, Jurado-Román A, Tébar-Márquez D, et al. Role of dynamic road-mapping in renal denervation procedures. J Invasive Cardiol 2024;36. doi: 10.25270/jic/24.00064. DOI: https://doi.org/10.25270/jic/24.00064

Cohen DL, Weinberg I, Uretsky S, et al. Imaging strategies for safety surveillance after renal artery denervation. Clin Res Cardiol 2021;110:609-19. DOI: https://doi.org/10.1007/s00392-021-01819-w

White RD, Moore KS, Salahia MG, et al. Renal arteries revisited: anatomy, pathologic entities, and implications for endovascular management. Radiographics 2021;41:909-28. DOI: https://doi.org/10.1148/rg.2021200162

Zeijen VJM, Feyz L, Nannan Panday R, et al. Long-term follow-up of patients undergoing renal sympathetic denervation. Clin Res Cardiol 2022;111:1256-68. DOI: https://doi.org/10.1007/s00392-022-02056-5

Pathak A, Boulestreau R, Sapoval M, et al. Catheter-based renal denervation in the treatment of arterial hypertension: an expert consensus statement on behalf of the French Society of Hypertension (SFHTA), French Society of Radiology (SFR), French Society of Interventional Cardiology (GACI), French Society of Cardiology (SFC), French Association of Private Cardiologists (CNCF), French Association of Hospital Cardiologists (CNCH), French Society of Thoracic and Cardiovascular Surgery (SFCTCV) and French Society of Vascular and Endovascular Surgery (SCVE). Arch Cardiovasc Dis 2024;117:601-11. DOI: https://doi.org/10.1016/j.acvd.2024.05.122

Mazza A, Dell’Avvocata F, Torin G, et al. Does renal denervation a reasonable treatment option in a haemodialysis-dependent patient with resistant hypertension? A narrative review. Curr Hypertens Rep 2023;25:353-63. DOI: https://doi.org/10.1007/s11906-023-01264-2

Società Italiana dell’Ipertensione Arteriosa (SIIA). Checklist for renal denervation. 2024. Available from: https://siia.it/wp-content/uploads/2024/11/Checklist-RDN-DEF-2024-ottobre.pdf

Yamamoto E, Sueta D, Tsujita K. Renal denervation in resistant hypertension: a review of clinical trials and future perspectives. Cardiovasc Interv Ther 2022;37:450-7. DOI: https://doi.org/10.1007/s12928-022-00854-2

Reyes KRL, Rader F. Long-term safety and antihypertensive effects of renal denervation: current insights. Integr Blood Press Control 2023;16:59-70. DOI: https://doi.org/10.2147/IBPC.S392410

Brouwers S, Botti G, Verbesselt M, et al. Catheter-based renal denervation for resistant arterial hypertension: 10-year real-world follow-up data. J Clin Hypertens 2024;26:1521-7. DOI: https://doi.org/10.1111/jch.14931

Saville KA, Zeijen VJM, Zietse R, et al. Percutaneous renal denervation in the management of kidney-related pain syndromes: a case series. Cardiovasc Revasc Med 2026;82:15-20. DOI: https://doi.org/10.1016/j.carrev.2025.04.041

Ziakas A, Petroglou D, Moralidis E, et al. Initial experience with renal denervation for the treatment of resistant hypertension — the utility of novel anesthetics and metaiodobenzylguanidine scintigraphy (MIBG). Open Cardiovasc Med J 2016;10:163-70. DOI: https://doi.org/10.2174/1874192401610010163

Kiuchi MG, Esler MD, Fink GD, et al. Renal denervation update from the International Sympathetic Nervous System Summit: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:3006-17. DOI: https://doi.org/10.1016/j.jacc.2019.04.015

Zhang J, Belford PM, Stouffer GA. Renal denervation after USA FDA approval: an update from an interventional cardiologist’s perspective. J Clin Med 2025;14:3554. DOI: https://doi.org/10.3390/jcm14103554

Barbato E, Azizi M, Schmieder RE, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the EAPCI. EuroIntervention 2023;18:1227-43. DOI: https://doi.org/10.4244/EIJ-D-22-00723

Skowerski T, Skowerski M, Kułach A, et al. Angio-computed tomography reveals differences in the anatomy of renal arteries in resistant hypertension patients qualified for renal denervation versus pseudo-resistant hypertensive subjects. Cardiol J 2023;30:379-84. DOI: https://doi.org/10.5603/CJ.a2021.0026

Kandzari DE, Mahfoud F, Townsend RR et al. Three-year durability of radiofrequency renal denervation: SPYRAL HTN-ON MED. J Am Heart Assoc 2026;15:e049081. DOI: https://doi.org/10.1161/JAHA.126.049081

Mahfoud F, Böhm M, Schmieder R, et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J 2019;40:3474-82. DOI: https://doi.org/10.1093/eurheartj/ehz118

Sharp ASP, Cao KN, Esler MD, et al. Cost-effectiveness of catheter-based radiofrequency renal denervation for uncontrolled hypertension: an analysis for the UK. Eur Heart J Qual Care Clin Outcomes 2024;10:698-708. DOI: https://doi.org/10.1093/ehjqcco/qcae001

Rodríguez-Leor O, Ryschon AM, Cao KN et al. Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Spain. REC Interv Cardiol. 2024;6:305-12. DOI: https://doi.org/10.24875/RECICE.M24000475

Kahan T, Johansen ML, Ryschon AM et al. Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Sweden. Blood Press 2025;34:2487583 DOI: https://doi.org/10.1080/08037051.2025.2487583

Kyriakoulis KG, Vakka A, Iliakis P et al. Cost-effectiveness of renal denervation: a systematic review and meta-analysis. Hypertens Res. 2026;49:1713-25. DOI: https://doi.org/10.1038/s41440-026-02578-9

Spiazzi BF, Zingano CP, Laffin LJ. Addressing hypertension treatment disparities via renal denervation. Curr Hypertens Rep 2026;28:9. DOI: https://doi.org/10.1007/s11906-025-01359-y